The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study
Open accessAbstract
Patients with multiple myeloma (MM) have an increased risk of venous thrombosis. Interestingly, excess risk of venous thromboembolism has been observed among patients with monoclonal gammopathy of undetermined significance (MGUS). Using population-based data from Sweden, we assessed the risks of venous and arterial thrombosis in 18,627 MM and 5326 MGUS patients diagnosed from 1958 to 2006, compared with 70,991 and 20,161 matched controls, respectively. At 1, 5, and 10 years after MM diagnosis, there was an increased risk of venous thrombosis: hazard ratios (95% confidence intervals) were 7.5 (6.4-8.9), 4.6 (4.1-5.1), and 4.1 (3.8-4.5), respectively. The corresponding results for arterial thrombosis were 1.9 (1.8-2.1), 1.5 (1.4-1.6), and 1.5 (1.4-1.5). At 1, 5, and 10 years after MGUS diagnosis, hazard ratios were 3.4 (2.5-4.6), 2.1 (1.7-2.5), and 2.1 (1.8-2.4) for venous thrombosis. The corresponding risks for arterial thrombosis were 1.7 (1.5-1.9), 1.3 (1.2-1.4), and 1.3 (1.3-1.4). IgG/IgA (but not IgM) MGUS patients had increased risks for venous and arterial thrombosis. Risks for thrombosis did not vary by M-protein concentration (> 10.0 g/L or < 10.0 g/L) at diagnosis. MGUS patients with (vs without) thrombosis had no excess risk of MM or Waldenström macroglobulinemia. Our findings are of relevance for future studies and for improvement of thrombosis prophylaxis strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is also an increased incidence of venous thromboembolism compared to the general population [57].”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [57]
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism
Heit, J. A., Silverstein, M. D., Mohr, D. N., Petterson, T. M., O’Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.809 · Cited by 2,172
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Facon, T. T. F., Mary, J., Hulin, C., Benboubker, L., Attal, M., Pegourié, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 864
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68338-4 · Cited by 802
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Barlogie, B., Desikan, R. K., Eddlemon, P., Spencer, T., Zeldis, J. B., Munshi, N. C., Badros, A. Z., Zangari, M., Anaissie, E. J., Epstein, J., et al. (2001) · Blood · doi:10.1182/blood.v98.2.492 · Cited by 539
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Zangari, M., Anaissie, E. J., Barlogie, B., Badros, A. Z., Desikan, R. K., Gopal, A. V., Morris, C., Toor, A. A., Siegel, E. R., Fink, L. M., et al. (2001) · Blood · doi:10.1182/blood.v98.5.1614 · Cited by 490
Venous thromboembolism: disease burden, outcomes and risk factors
Heit, J. A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01415.x · Cited by 448
Hazard Rate Estimation under Random Censoring with Varying Kernels and Bandwidths
Müller, H., & Wang, J. (1994) · Biometrics · doi:10.2307/2533197 · Cited by 347
Kristinsson, S. Y., Landgren, O., Dickman, P. W., Derolf, Å. R., & Björkholm, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0100 · Cited by 322
Self-citationZangari, M., Siegel, E. R., Barlogie, B., Anaissie, E. J., Saghafifar, F., Fassas, A., Morris, C., Fink, L. M., & Tricot, G. J. K. (2002) · Blood · doi:10.1182/blood-2002-01-0335 · Cited by 261
Lenalidomide and Venous Thrombosis in Multiple Myeloma
Knight, R., DeLap, R. J., & Zeldis, J. B. (2006) · New England Journal of Medicine · doi:10.1056/nejmc053530 · Cited by 234
Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma
Osman, K., Comenzo, R. L., & Rajkumar, S. V. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442516 · Cited by 228
Baz, R., Li, L., Kottke‐Marchant, K., Srkalović, G., McGowan, B. R., Yiannaki, E. O., Karam, M. A., Faiman, B. M., Jawde, R. M. A., Andresen, S. W., et al. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.12.1568 · Cited by 228
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
Kristinsson, S. Y., Fears, T. R., Gridley, G., Turesson, I., Mellqvist, U., Björkholm, M., & Landgren, O. (2008) · Blood · doi:10.1182/blood-2008-04-151076 · Cited by 198
Self-citationSrkalović, G., Cameron, M. G., Rybicki, L. A., Deitcher, S. R., Kattke‐Marchant, K., & Hussein, M. A. (2004) · Cancer · doi:10.1002/cncr.20405 · Cited by 172
Landgren, O., Kristinsson, S. Y., Goldin, L. R., Caporaso, N. E., Blimark, C. H., Mellqvist, U., Wåhlin, A., Björkholm, M., & Turesson, I. (2009) · Blood · doi:10.1182/blood-2008-12-191676 · Cited by 167
Self-citationKristinsson, S. Y., Björkholm, M., Goldin, L. R., McMaster, M. L., Turesson, I., & Landgren, O. (2008) · Blood · doi:10.1182/blood-2008-06-162768 · Cited by 163
Self-citationCavo, M., Zamagni, E., Cellini, C., Tosi, P., Cangini, D., Cini, M., Valdré, L., Palareti, G., Masini, L., Tura, S., et al. (2002) · Blood · doi:10.1182/blood-2002-06-1674 · Cited by 152
Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer
Bennett, C. L., Angelotta, C., Yarnold, P. R., Evens, A. M., Zonder, J. A., Raisch, D. W., & Richardson, P. G. G. (2006) · JAMA · doi:10.1001/jama.296.21.2558-c · Cited by 149
Thalidomide and rituximab in Waldenstrom macroglobulinemia
Treon, S. P., Soumerai, J. D., Branagan, A. R., Hunter, Z. R., Patterson, C. J., Ioakimidis, L., Briccetti, F., Pasmantier, M. W., Zimbler, H., Cooper, R. B., et al. (2008) · Blood · doi:10.1182/blood-2008-04-150854 · Cited by 142
Zonder, J. A., Barlogie, B., Durie, B. G. M., McCoy, J., Crowley, J. J., & Hussein, M. A. (2006) · Blood · doi:10.1182/blood-2006-01-0154 · Cited by 138
Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Treon, S. P., Soumerai, J. D., Branagan, A. R., Hunter, Z. R., Patterson, C. J., Ioakimidis, L., Chu, L., Musto, P., Baron, A. D., Nunnink, J. C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0862 · Cited by 128
Treatment of Waldenstrom’s Macroglobulinemia With Thalidomide
Dimopoulos, M. A., Zomas, A., Viniou, N. A., Grigoraki, V., Galani, E. P., Matsouka, C., Economou, O., Anagnostopoulos, N. I., & Panayiotidis, P. G. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3596 · Cited by 127
Turesson, I., Linet, M. S., Björkholm, M., Kristinsson, S. Y., Goldin, L. R., Caporaso, N. E., & Landgren, O. (2007) · International Journal of Cancer · doi:10.1002/ijc.22912 · Cited by 124
Self-citationKristinsson, S. Y., Björkholm, M., Andersson, T., Eloranta, S., Dickman, P. W., Goldin, L. R., Blimark, C. H., Mellqvist, U., Wåhlin, A., Turesson, I., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.010066 · Cited by 112
Self-citationSallah, S., Husain, A., Wan, J. Y., Vos, P. W., & Nguyen, N. P. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh385 · Cited by 84
Hussein, M. A. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-02-0080 · Cited by 69
Thromboembolic events during treatment with thalidomide
Urbauer, E., Kaufmann, H., Nösslinger, T., Raderer, M., & Drach, J. W. (2002) · Blood · doi:10.1182/blood-2001-12-0245 · Cited by 68
Zangari, M., Tricot, G. J. K., Polavaram, L., Zhan, F., Finlayson, A., Knight, R., Fu, T., Weber, D., Dimopoulos, M. A., Niesvizky, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0169 · Cited by 58
Thromboembolic Complications in Myelomatosis
Catovsky, D., IKOKU, N. B. I., Pitney, W. R., & Galton, D. A. G. (1970) · BMJ · doi:10.1136/bmj.3.5720.438 · Cited by 50
Arterial thrombosis in four patients treated with thalidomide
Scarpace, S., Hahn, T., Roy, H., Brown, K., Paplham, P., Chanan-Khan, A., van Besien, K., & McCarthy, Jr. (2005) · Leukemia & Lymphoma · doi:10.1080/10428190400015675 · Cited by 50
Prothrombotic Coagulation Abnormalities in Patients with Paraprotein-Producing B-Cell Disorders
Auwerda, J. J. A., Sonneveld, P., de Maat, M. P. M., & Leebeek, F. W. G. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.n.027 · Cited by 41
Thromboembolism in Patients on Thalidomide for Myeloma
Bowcock, S. J., Rassam, S. M. B., Ward, S. M., Turner, J. T., & Laffan, M. (2002) · Hematology · doi:10.1080/10245330290020126 · Cited by 40
Cohen, A. L., & Sarid, R. (2009) · Thrombosis Research · doi:10.1016/j.thromres.2009.01.004 · Cited by 26
Arterial thrombosis and thalidomide
Göz, M., Eren, M., & Cakir, O. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0057-1 · Cited by 22
Arterial and Venous Thrombotic Complications with Thalidomide in Multiple Myeloma
Alkindi, S. S. A., Dennison, D., & Pathare, A. V. (2007) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.08.005 · Cited by 21
Thalidomide causes platelet activation, which can be abrogated by aspirin
Dunkley, S. M., & Gaudry, L. E. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02542.x · Cited by 19
Stroke in a Multiple Myeloma Patient Treated With Thalidomide
Ortı́n, X., Rodríguez‐Luaces, M., Calabuig, M., & Font, L. (2006) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2006.06.005 · Cited by 14
Thalidomide-associated Arterial Thrombosis: Two Case Reports
Altıntaş, A., Ayyildiz, O. M., Atay, A. E., Çil, T., Işıkdoğan, A., & Müftüoğlu, E. (2007) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v36n4p304 · Cited by 13
Kristinsson, S. Y., Björkholm, M., Goldin, L. R., Blimark, C. H., Mellqvist, U., Wåhlin, A., Turesson, I., & Landgren, O. (2008) · Blood · doi:10.1182/blood.v112.11.1678.1678 · Cited by 2
Self-citation
Research works printed but not linked: 3
- Rajkumar, 2006, Lenalidomide and venous thrombosis in multiple myeloma., N Engl J Med, 354, 2079, 10.1056/NEJMc053530 · DOI
- Socialstyrelsen, 2007, Cancer Incidence in Sweden 2006
- Anonymous, 1998, Patientregistret 1987-1996: Kvalitet och innehåll (Swedish)
Cited by
Sorted by citations
Epidemiology, Staging, and Management of Multiple Myeloma
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332
“thromboembolism compared to the general population [57].”
Larocca, A., Cavallo, F., Bringhen, S., Raimondo, F. D., Falanga, A., Evangelista, A., Cavalli, M. M., Stanevsky, A., Corradini, P., Pezzatti, S., et al. (2011) · Blood · doi:10.1182/blood-2011-03-344333 · Cited by 292
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 263
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Callander, N. S., Baljević, M., Adekola, K., Anderson, L. D., Campagnaro, E. L., Castillo, J. J., Costello, C. L., Devarakonda, S. S., Elsedawy, N., Faiman, M., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0002 · Cited by 210
Venous and Arterial Thromboembolism in Patients With Cancer
Gervaso, L., Dave, H. M., & Khorana, A. A. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.03.001 · Cited by 181
Metadata
- Authors
- Kristinsson, S. Y., Pfeiffer, R. M., Björkholm, M., Goldin, L. R., Schulman, S., Blimark, C., Mellqvist, U.-H., Wahlin, A., Turesson, I., & Landgren, O.
- Affiliations
- Karolinska University Hospital (SE)
- National Institutes of Health (US)
- Sahlgrenska University Hospital (SE)
- Cancer Centre, Section of Hematology, Umea University Hospital, Umea, Sweden;
- Department of Medicine, Section of Hematology, Malmö University Hospital, Malmö, Sweden; and
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-06-17
- Volume
- 115
- Issue
- 24
- Pages
- 4991-4998
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC2890150
- OpenAlex
- W1975136159
- Cited by
- 255
- References
- 44
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 21 · 2023: 25 · 2022: 19 · 2021: 17 · 2020: 20 · 2019: 14 · 2018: 11 · 2017: 10 · 2016: 19 · 2015: 10 · 2014: 15 · 2013: 9 · 2012: 13
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- monoclonal gammopathy of undetermined significance, multiple myeloma, venous thrombosis, arterial thrombosis, venous thromboembolism, Waldenström macroglobulinemia, thrombosis risk, thromboprophylaxis
- MeSH terms
- Adult, Aged, Aged, 80 and over, Arteries, Female, Humans, Immunoglobulin A, Immunoglobulin G, Waldenstrom Macroglobulinemia, Male, Middle Aged, Multiple Myeloma, Paraproteinemias, Predictive Value of Tests, Registries, Risk Factors, Sweden, Veins, Proportional Hazards Models, Survival Analysis, Databases, Factual, Venous Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
